Stammdaten
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Allarity Therapeutics, Inc. |
|---|---|
| Ticker | ALLR |
| CIK | 0001860657 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 21,9 Mio. USD |
| Beta | 0,01 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -11,231,000 | 18,258,000 | 9,828,000 | ||
| 2025-09-30 | 10-Q | -2,806,000 | 20,796,000 | 12,011,000 | ||
| 2025-06-30 | 10-Q | -2,320,000 | 21,205,000 | 12,167,000 | ||
| 2025-03-31 | 10-Q | -2,732,000 | 29,730,000 | 18,669,000 | ||
| 2024-12-31 | 10-K | -24,515,000 | 22,650,000 | 11,811,000 | ||
| 2024-09-30 | 10-Q | -11,590,000 | 20,378,000 | 12,964,000 | ||
| 2024-06-30 | 10-Q | -1,629,000 | -0.11 | 30,883,000 | 19,835,000 | |
| 2024-03-31 | 10-Q | -3,843,000 | -22.14 | 11,969,000 | -6,471,000 | |
| 2023-12-31 | 10-K | -11,901,000 | -10.26 | 11,862,000 | -2,751,000 | |
| 2023-09-30 | 10-Q | -4,447,000 | -2.03 | 13,875,000 | -3,379,000 | |
| 2023-06-30 | 10-Q | -2,380,000 | -525.53 | 13,426,000 | -723,000 | |
| 2023-03-31 | 10-Q | -3,352,000 | -###.## | 12,702,000 | -3,102,000 | |
| 2022-12-31 | 10-K | -16,058,000 | -###.## | 14,544,000 | -113,000 | |
| 2022-09-30 | 10-Q | -5,037,000 | -934.29 | 18,134,000 | 1,447,000 | |
| 2022-06-30 | 10-Q | -5,103,000 | -53.90 | 23,231,000 | 7,966,000 | |
| 2022-03-31 | 10-Q | -3,080,000 | -19.64 | 31,290,000 | 14,732,000 | |
| 2021-12-31 | 10-K | -26,648,000 | -4.19 | 49,633,000 | 18,152,000 | |
| 2021-09-30 | 10-Q | -1,351,000 | -0.17 | 36,987,000 | 29,661,000 | |
| 2021-06-30 | 10-Q | -5,396,000 | -1.08 | 28,823,000 | ||
| 2021-03-31 | 10-Q | -3,085,000 | 23,468,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.